Latest News

LEO orders Hitgen to discover new leads

© LEO Pharma


by ml

In a multi-year collaboration with LEO Pharma A/S, Chinese Hitgen is poised to discover novel small molecule leads for multiple therapeutic targets chosen by the Danish skin treatment specialist.

A multi-year Danish-Chinese collaboration has been agreed upon in early August. Using its large DNA-encoded library of novel leads, Hitgen Ltd. of Chengdu will discover novel small molecule leads for multiple targets specified by LEO Pharma A/S, a Danish dermatology company based in Ballerup. Hitgen has established discovery partnerships with major global pharmas, including Janssen, Merck, Pfizer and the Scripps Research Institute. Under the terms of the LEO agreement, Hitgen will receive an upfront payment and be eligible for milestones. More specifically, Hitgen will use its advanced technology platform, based on DNA-encoded library design, synthesis and screening to discover novel leads which will be licensed exclusively to LEO Pharma. “We are excited by renewing and extending our collaboration with Hitgen” said Thorsten Thormann, Vice President of Research at LEO Pharma. “We are looking forward to expand our ability to identify new leads for multiple target families.“

© european-biotechnology.com/ml

BASF broadens biotech business by Isobionics acquisition

The acquisition of Isobionics BV (Geleen, The Netherlands) gives the the German world chemistry leader a foothold in the growing US$20.75bn market...

4SC expands domatinostat combo testing

In an investigator-initiated Phase Ib study (DONIMI) at NKI, 40 patients with melanoma will be enrolled  before surgery (neoadjuvant setting) to...

Zealand Pharma acquires Encycle

Under the agreement, Zealand Pharma A/S will acquire all outstanding shares in Encycle Therapeutics Inc., and all its intellectual property,...

Protein protects against liver fibrosis

In mice, a team headed by Philipp Lang from University Düsseldorf, Germany, showed that the iRhom2 protein counteracted the injury- and...

GHO capital launches EU's largest fund ever for life sciences

Global Healthcare Opportunities, or GHO Capital Partners LLP said that its finally closed Fund II will be focussed on high growth healthcare...

PFF Group NV acquires stake in Autolus Therapeutics

With the investment into London-headquartered Autolus Therapeutics, PPF Group N.V. significantly increased its commitment to the healthcare sector....

EU with poor success in fighting superbugs

Although some progress has been made through EU action, there is little evidence so far to suggest that the health burden of antimicrobial resistance...